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Objectives: HIGH-density lipoproteins (HDL) are a negative predictor of platelet-dependent thrombus
formation and reducedplatelet activationhas beenobserved in vitro in thepresence ofHDL3, amajorHDL
fraction. However, mechanisms underlying the anti-thrombotic effects of HDL3 are poorly understood.
Scavenger receptors class B represent possible HDL3 binding partners on platelets. We here investigated
the role of scavenger receptor class B type I (SR-BI) and CD36 in mediating inhibitory effects of native
HDL3 on thrombin-induced platelet activation.
Methods and results: Rhodamine isothiocyanate-labeled HDL3 bound speciﬁcally to platelets and HDL3
binding was inhibited by scavenger receptor class B ligands such as phosphatidylserine (PS)- or
phosphatidylinositol (PI)-containing liposomes or maleylated albumin (mBSA). By contrast, scavenger
receptor class A ligands failed to displace HDL3 from platelets. HDL3, PS- and PI-liposomes, and mBSA
inhibited thrombin-induced platelet aggregation, ﬁbrinogen binding, P-selectin expression and mobi-
lization of intracellular Ca2+. In addition, PS- and PI-liposomes emulated HDL3-induced intracellular
signaling cascades including diacylglycerol production and protein kinase C activation. The reduction of
platelet activationby liposomeswas related to their PS or PI content.Moreover, inhibitory effects of native
HDL3 were enhanced after enriching lipoproteins with PS, while PS- and PI-poor HDL2 failed to inhibit
platelet aggregation and Ca2+ mobilization. Both, HDL3 and PS-containing liposomes failed to inhibit
thrombin-inducedactivationofplatelets obtained fromSR-BI-deﬁcientmicebutnotCD36-deﬁcientmice.
Conclusion: We suggest that SR-BI is a functional receptor for native HDL3 on platelets that generates an
inhibitory signal for platelet activation. The content of negatively charged phospholipids (PS, PI) in HDL
erminmay be an important det
. IntroductionPlatelets are intimately involved in the initiation and the
rogression of atherosclerosis [1–3]. Proinﬂammatory cytokines,
hemokines and growth regulatory molecules liberated from
latelets promote endothelial dysfunction andalter smoothmuscle
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© 2011 Elsevier Ireland Ltd. 
cell function. In addition, platelets direct leukocyte incorpora-
tion into plaques through platelet-mediated leukocyte adhesion.
Activated platelets and their aggregates with leukocytes were
repeatedly reported in patients with atherothrombotic vascular
disease [4,5]. Conversely, decreased formation of atherosclerotic
lesions has been observed in animals with thrombocytopenia [6].
High-density lipoproteins (HDL) represent a major anti-
Open access under the Elsevier OA license.atherogenic factor in plasma. Several studies documented
inhibitory effects of HDL on the agonist-induced platelet activa-
tion both under in vitro and ex vivo conditions [7,8]. In addition,
a strong inverse association exists between plasma HDL levels and
recurrent venous thromboembolism, andHDL cholesterol has been
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dentiﬁed as an independent predictor of acute platelet thrombus
ormation [9,10]. However, mechanisms underlying the inhibitory
ffects of on platelet activation are not completely understood.
e previously demonstrated that HDL3, a major HDL fraction,
nduceaPKC-dependent inhibitionofphosphatidylinositol-speciﬁc
hospholipase C (PI-PLC) as well as cytoplasm alkalization, ulti-
ately attenuating platelet aggregation, granule secretion and
brinogen binding in response to thrombin [11,12]. The objec-
ive of the present study was to speciﬁcally investigate the
olecular events located upstream to this second messenger
ascade in platelets exposed to HDL3. By using functional ago-
ists of the scavenger receptor type B family as well as platelets
rom animals deﬁcient in CD36 or scavenger receptor B type I
SR-BI) we demonstrate for the ﬁrst time that native HDL3 mod-
late platelet activation in a SR-BI-dependent process. Our data
urther indicate that the content of negatively charged phospho-
ipids such as phosphatidylserine (PS) and phosphatidylinositol
PI) in HDL3 modulates the interaction between HDL3 and SR-
I and thereby determines the anti-thrombotic potential of these
ipoproteins.
. Methods
.1. Materials
Thrombin, fura 2-AM, rhodamine isothiocyanate (RITC), ﬂu-
resceine isothiocyanate (FITC), bovine serum albumin (BSA),
hospholipids, and inorganic reagents were from Sigma Chemical
ompany, Deisenhofen, Germany. [33P]orthophosphoric acid was
urchased from NEN-DuPont, Dreieich, Germany. [14C]arachidonic
cid (AA) and Sephadex G-25 columns were from GE Health-
are, München, Germany. Silica gel 60 plates and solvents for TLC
ere obtained from Merck, Darmstadt, Germany. Calphostin C,
is-indolylmaleimide (GF109203X), D609, and GLY-PRO-ARG-PRO
GPRP) were obtained from Merck, Bad Soden, Germany. Highly
uriﬁed, plasminogen-free ﬁbrinogen was supplied by Enzyme
esearch Labs. Monoclonal anti-CD62P antibody was from Beck-
anCoulter, Krefeld, Germany.
.2. Animals
Class B, type I scavenger receptor, SR-BI, knockout mice
ere kindly provided by Dr. M. Krieger (Biology Department,
assachusetts Institute of Technology, Cambridge, MA) [13].
eterozygous SR-BI knockout mice were crossed to generate
omozygous mutant (SR-BI−/−) progeny. The presence of the tar-
eted and/or wild type SR-BI alleles was determined by PCR
mpliﬁcation of DNA extracted from tail biopsies. CD36−/− mice
ere kindly provided by Dr. M. Febbraio (Department of Medicine,
eill Medical College of Cornell University, New York, USA) [14].
ice had ad libitum access to water and regular chow diet. All
nimal protocols used in this study conformed to national law
nd were approved by the Ethics Committee for Animal Experi-
ents of the Landesamt für Natur, Umwelt und Verbraucherschutz
ordrhein-Westfalen (LANUV).
.3. Lipoprotein isolation and modiﬁcation
HDL3 (d=1.125–1.210g/mL) and HDL2 (d=1.063–1.125g/mL)
ere isolated from human plasma by discontinuous KBr gradi-
nts as described by Havel et al. [15]. HDL fractions were dialyzed
gainst 0.3mmol/L Tris–HCl, 0.14mol/L NaCl, 1.0mmol/L EDTA,
H 7.2, concentrated using the Minicon B15 concentrator (Ami-
on), and stored in the dark at 4 ◦C for no longer than 7 days.
DTA was removed by dialysis shortly before experimentation.
o effects of storage on the HDL3 electrophoretic mobility andsis 215 (2011) 374–382 375
the content of thiobarbituric acid-reactive substances (TBARS)
were noted. To enrich HDL3 with anionic phospholipids, PS in
amounts corresponding to 0.5% and 1% of estimated total lipopro-
tein weight was dried under N2 and vigorously vortexed with
native HDL3 for 30min. Lipoproteins were reisolated by ultra-
centrifugation thereafter. HDL3 was labeled with RITC exactly
as described [16]. Brieﬂy, HDL3 (10.0 g/L) were diluted 1:2 (v/v)
with 0.2mol/L Na2HPO4 and 0.02mg of RITC per 1.0mg HDL3
was added to the HDL3 solution under continuous stirring. The
lipoprotein–RITC mixture was adjusted to pH 9.5 with 0.01mol/L
NaOH. The mixture was incubated in the dark at room temperature
for 30min and RITC–HDL3 were separated from unbound dye on a
Sephadex G-25 column and dialyzed against the EDTA-containing
buffer, pH 7.2.
Low-density lipoproteins (LDL, d=1.019–1.063g/mL) were iso-
lated, dialyzed and stored as described for HDL3. For acetylation,
LDL (3.0mg/mL) were mixed 1:1 (v/v) with saturated sodium
acetate on ice under continuous stirring. Thereafter, acetate anhy-
dride was added dropwise within 1h in a volume (L) equivalent
to protein concentration (g/mL)×1.5. The pH was kept constant
at 7.4 during the procedure.
HDL-free platelet-rich plasmawas obtained by reconstitution of
lipoprotein-depleted plasma with homologous very-low-density,
intermediary-density, and low-density lipoproteins tooriginal con-
centrations and with washed platelets (5×108/mL).
2.4. Preparation of liposomes and maleylated bovine serum
albumin (mBSA)
Chloroform solutions (1mg/mL) of phosphatidylcholine (PC),
PS or PI were mixed in a desired molar ratio, dried under nitro-
gen and lyophilized. Phospholipids were resuspended in PBS under
vigorous vortexing and unilamellar liposomes were produced by
extrusion through a polycarbonate membrane (0.1m pore diam-
eter). For bovine albumin maleylation, 0.1mg BSA in 0.2mol/L
Na2B407, pH 8.5 was reacted with an excess maleic anhydride
according to a published method [17]. The reaction mixture was
dialyzed against 0.1mol/L NH4HCO3, then against Tris–HCl buffer,
and lyophilized.
2.5. Determination of phospholipid concentrations
Phospholipids were extracted from HDL fractions or liposomes
according to Bligh andDyer [18] and concentrations of PC, PS and PI
were determined by high pressure liquid chromatography (HPLC)
with light scattering detection exactly as described by Silversand
and Haux [19].
2.6. Platelet isolation and incubation
For human platelets, venous blood was drawn from healthy
volunteers aged 25–55 years into 5mL tubes containing 0.5mL
of 0.1mol/L trisodium citrate solution. For mouse platelets, blood
was drawn into silanized capillaries by retro-orbital puncture and
anti-coagulated with citrate. Blood was centrifuged at 120× g for
10min. Platelet-rich plasma was collected, mixed with acid cit-
rate dextrose (ACD; 6.0mmol/L citric acid, 12.0mmol/L trisodium
citrate, and 19.4mmol/L glucose (1:3 v/v)) and centrifuged at
1000× g for 10min. Platelets were resuspended in a buffer con-
taining 5.0mmol/Lmmol/L HEPES, 145mmol/L NaCl, 5.0mmol/L
KCl, 5.0mmol/L glucose, 1.1mmol/L NaHCO3, and 0.35% BSA (w/v).
Platelets were incubated with indicated concentrations of HDL3,
HDL2, liposomes or mBSA for 5min prior to stimulation with
thrombin. Platelet number (5×108/mL) was kept constant during
experiments.
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.7. Platelet cholesterol content
To determine total cholesterol content in platelets, cells
5×108/mL) were extracted 3×with ethyl acetate (1:1, v/v), and
he solventwas evaporated under nitrogen. The residuewas recon-
tituted in PBS containing 0.05% Tween 20 and the cholesterol
ontent was determined using colorimetric method (cholesterol
xidase/peroxidase) on the clinical laboratory analyzer (Advia
800, Siemens, Germany)
.8. Flow cytometric analysis of RITC–HDL3 binding on platelet
urface
For analysis of HDL3 binding to the platelet surface, we adopted
procedure previously established in our laboratory for leukocytes
16]. Platelets were pre-incubated at 4 ◦C with HDL3, liposomes,
BSA or the equal volume of buffer for 30min, incubated with the
ndicated amount of RITC–HDL3 for 1h in a total volume of 0.25mL,
ashed and analyzedwith a FACScan ﬂow cytometer (BectonDick-
nson, Heidelberg, Germany) equipped with a 488nm argon laser.
ach value was determined from the signals collected from 5000
ells, and calculations were based on the mean ﬂuorescence.
.9. Flow cytometric analysis of ﬁbrinogen binding and CD62
xpression on the platelet surface
Platelet surface ﬁbrinogen binding and CD62 expression were
etermined exactly as described previously [11]. Brieﬂy, human
brinogen was conjugated with FITC using the FITC-celite method
ccording to Xia et al. [20]. Protein/FITC ratio was 1:5. Platelet
uspensions (0.2mL) pre-incubated for 5min at room tempera-
urewith 0.15g/L ﬁbrinogen-FITC andwith eitherHDL3, liposomes,
BSA or the equivalent volume of buffer were added to 0.02mL of
solution containing increasing concentrations of thrombin. The
eaction was performed in the presence of 1.25mmol/L GPRP (an
nhibitor of ﬁbrin polymerization) and was stopped after 180 s by
xation in 1% formaldehyde for 30min. For antigen expression
nalysis, FITC-coupled monoclonal antibody recognizing CD62 was
dded after ﬁxation for 45min.
.10. Platelet aggregation
Platelet aggregationwasmonitored in theElvi611aggregometer
djusted to its maximal sensitivity as described previously [11].
.11. Determination of intracellular Ca2+ concentration
Intracellular calcium measurements were performed exactly as
escribed previously [11,12].
.12. Determination of diacylglycerol (DAG) production
Determination of DAG formation was accomplished as
escribed previously [11]. Brieﬂy, platelets were incubated for
0min with 0.1Ci/mL [14C]arachidonic acid at 30 ◦C. After stimu-
ation with thrombin, aliquots (0.5mL) were withdrawn and added
o 1.5mL of ice-cold chloroform/methanol (2:1, v/v). Radiolabeled
ipidswere extracted according to Bligh andDyer [18] and analyzed
y thin layer chromatography as described by Gruchalla et al. [21].
lates were analyzed with a BAS 1500 phosphoimager (Fuji Film)..13. Determination of protein phosphorylation
Platelets were labeled with 0.1mCi/mL [33P]orthophosphoric
cid for 90min at 37 ◦C, washed, and adjusted to 1×109/mL.
fter stimulation with thrombin, the reactions were terminated bysis 215 (2011) 374–382
adding 10% TCA (1:1 v/v). The precipitate was washed twice, dis-
solved in 0.1mL of NaOH (0.2mol/L), mixed with an equal volume
of double-concentrated sample buffer, and subjected to SDS-PAGE.
Dried gels were analyzed by phosphoimaging.
2.14. Determination of thrombin activity
Thrombin at indicated concentrations was incubated with lipo-
somes, HDL3 or hirudin (Loxo, Dossenheim, Germany) as positive
control for 5min. Thereafter the thrombin substrate Pefachrome
TH (Pentapharm, Basel, Switzerland) was added and the optical
density was measured at 405nm using Tecan Sunrise ELISA reader
(Männedorf, Switzerland). Data were calculated as the maximum
slope (OD/min).
2.15. Statistical analysis
Data are presented as means± SD from three separate exper-
iments or as results representative for at least three repetitions,
unless indicated otherwise. Comparisons between the groupswere
performed with two-tailed Student’s t-test.
3. Results
3.1. Scavenger receptors class B (SR-B) mediate HDL3 binding to
human platelets
To examine the possible role of SR-B asHDL3 receptor onhuman
platelets, we ﬁrst conducted equilibrium ligand binding analy-
sis using RITC–HDL3 as previously described for leukocytes [16].
As shown in Fig. 1A, increasing amounts of RITC–HDL3 bound to
platelets in a saturable fashion. Scatchard analysis of the speciﬁc
binding curve revealed the dissociation constant (Kd) of 68.42g
of HDL3 protein/mL close to those reported for the binding of HDL3
to SR-BI, when expressed on mammalian cells [22]. The binding
speciﬁcity of HDL3 to platelets was further explored by competi-
tion experiments with unlabeled SR-B ligands. As expected, native
HDL3 effectively suppressed binding of RITC–HDL3 to platelets
(Fig. 1B). Similarly, liposomes containing anionic phospholipids PS
or PI, which serve as ligands for SR-BI and CD36 [23], inhibited a
signiﬁcant portion of RITC–HDL3 binding to platelets (−50% inhi-
bition at −1.0 g/L native HDL3; Fig. 1C). By contrast, liposomes
containing only zwitterionic PC were ineffective at concentra-
tions as high as 5.0 g/L. The propensity of liposomes to displace
RITC–HDL3 from platelets was dependent on their anionic phos-
pholipid content with the maximal effect seen at equimolar PC:PS
or PC:PI ratios (Fig. 1D). In addition, RITC–HDL3 bound to platelets
could be displaced by mBSA, a lipid-free SR-B ligand [24], but not
by unmodiﬁed BSA (Fig. 1E). As scavenger receptors type A (SR-
A) are also expressed on platelets, we tested the effects of SR-A
ligands on RITC–HDL3 binding. As shown in Fig. 1F, neither polyi-
nosinic acid and polyadenylic acid, nor fucoidan – speciﬁc SR-A
ligands – affected RITC–HDL3 binding to human platelets. By con-
trast, RITC–HDL3 binding was effectively inhibited by acetylated
LDL (acLDL), which serves as a binding partner for both SR-A and
SR-B receptors (Fig. 1F) [24].
3.2. SR-B ligands inhibit human platelet activation
To determine whether the engagement of SR-B on the cell sur-
face results in modiﬁcation of platelet functions, we tested the
effects of HDL3, PS- and PI-containing liposomes as well as mBSA
on thrombin-induced aggregation and mobilization of intracel-
lular calcium. As shown in Fig. 2A and C, addition of thrombin
(0.02U/mL) to the platelet suspension resulted in parallel aggre-
gation and [Ca2+] elevation and both effects were inhibited after
M.F. Brodde et al. / Atherosclerosis 215 (2011) 374–382 377
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Fig. 1. Scavenger receptor type B but not type A ligands interfere with HDL3 binding to human platelets. (A) Human washed platelets were incubated with increasing
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oly(I) (©), poly(A) (), and fucoidan (♦). Data from panels B to F represent mean±
iposomes (panel B) or mBSA vs. BSA (panel E).
re-incubation of platelets for 5min with HDL3 at physiologi-
al concentrations (1.0 g/L). Both, PS- and PI-containing liposomes
0.5 g/L, PC:PS and PC:PI ratio 1:1, mol/mol) and mBSA (0.5 g/L)
re-incubated with platelets for 5min fully emulated the ability
f HDL3 to inhibit thrombin-induced aggregation and [Ca2+] ele-
ation, whereas PC-liposomes and unmodiﬁed BSA (not shown)
xerted no effect. The capacity of liposomes to inhibit platelet
ggregation and calcium mobilization was dependent on anionic
hospholipids and reached the maximum at equimolar PC:PS or
C:PI ratios (Fig. 2B and D).
Platelet activation is associated with the conformational change
f the integrinIIb3 enabling ﬁbrinogen binding and the secretion
f granular content accompanied by exposure of activation-
ependent glycoproteins such as P-selectin (CD62) on the platelet
urface. Therefore, we next compared the effects of HDL3 and SR-B
igands on thrombin-induced ﬁbrinogen binding and CD62 sur-
ace expression. As shown in Fig. 2E and F, exposure of platelets to
ncreasing concentrations of thrombin increased the surface bind-
ng of FITC-conjugated ﬁbrinogen and anti-CD62 with the binding
axima observed at agonist concentrations between 0.01U/mL
nd 0.05U/mL. Pre-incubation of platelets with HDL3 (1.0 g/L),()–speciﬁc HDL3 binding. Data represent means from 3 independent experiments.
- (), or PI- ()-containing liposomes (E) mBSA () or BSA (♦) (F) acetylated LDL (),
m 3 to 5 independent experiments. *p<0.01; **p<0.001 PC- vs. PS- or PI-containing
PS- or PI-containing liposomes (0.5 g/L, PC:PS and PC:PI ratio
1:1, mol/mol), or mBSA (0.5 g/L) for 5min prior to stimulation
with the agonist signiﬁcantly reduced both ﬁbrinogen binding
and CD62 surface exposure at lower thrombin concentrations (up
to 0.05U/mL). At higher thrombin concentrations, however, both
HDL3 and SR-B agonists exerted no appreciable inhibitory effect.
We next examined whether the inhibitory effects of SR-B ago-
nists on platelet activation are also exerted in a more physiological
environment. To this aim, we determined the effect of HDL3 as
well as PS- and PI-containing liposomes on ﬁbrinogen binding
and CD62 surface exposure in platelet-rich plasma deprived of
HDL3. As shown in Fig. 2G and H, reconstitution of HDL3-free
plasma with native lipoproteins reduced both thrombin-induced
ﬁbrinogenbindingandCD62surfaceexposureat loweragonist con-
centrations. Similar inhibitory effects were observed, when PS- or
PI-containing liposomes were used instead of HDL3.To address the possibility that SR-B agonists inhibit platelet
activation by directly binding thrombin and thereby diminishing
enzyme activity, the effect of HDL3, PS- or PI-containing lipo-
somes on thrombin-mediated degradation of the speciﬁc enzyme
substrate was examined. As shown in Table 1, neither native
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Fig. 2. Scavenger receptor type B ligands inhibit thrombin-induced activation of human platelets. Human washed platelets (A–F) or HDL-deprived platelet-rich plasma (G
and H) were stimulated with 0.02U/mL thrombin or with increasing concentrations of thrombin (Thr, ©) in the absence or presence of HDL3 (1.0 g/L, ), (PC-liposomes
(0.5 g/L)), PS-liposomes (0.5 g/L, ), PI-liposomes (0.5 g/L ), or mBSA (0.5 g/L, ). (A and B) Aggregation, (C and D) Ca2+ mobilization, (E and G) ﬁbrinogen binding, (F and
H) CD62 expression. Panels A and C show original tracings superimposed for comparison. Maximal stimulation with thrombin was set as 100%. Data from panels B, D,
E, F, G and H represent mean± SD from 3 to 6 independent experiments. *p<0.01; **p<0.001 thrombin vs. thrombin+HDL3, +liposomes or +mBSA. Panel E: signiﬁcant
differences between thrombin and thrombin+HDL3, +liposomes or +mBSA were observ
signiﬁcant differences between thrombin and thrombin+HDL3, +liposomes or +mBSA we
PI-liposomes – p<0.05; mBSA – p<0.01). Panel G: signiﬁcant differences between throm
0.1 (p<0.01; HDL3 and PI-liposomes – p<0.05). Panel H: signiﬁcant differences between t
and 0.1 (p<0.01).
Table 1
Effect of SR-B agonists on the thrombin activity.
Thrombin activity (optical density at 450nm/min)
Thrombin concentrations
(U/mL)
0.05 0.1 0.2
Control 0.112 ± 0.001 0.153 ± 0.002 0.236 ± 0.005
HDL3 (1.0mg/mL) 0.152 ± 0.003 0.235 ± 0.004 0.359 ± 0.008
PS-liposomes (0.5mg/mL) 0.150 ± 0.002 0.188 ± 0.001 0.345 ± 0.006
PI-liposomes (0.5mg/mL) 0.131 ± 0.003 0.198 ± 0.003 0.318 ± 0.006
Hirudin (10U/mL) 0.060 ± 0.001 0.061 ± 0.001 0.060 ± 0.001
Values represent means± SD from three determinations.ed at 0.01 U/mL (p<0.01), 0.03U/mL (p<0.01), and 0.05U/mL (p<0.01). Panel F:
re observed at 0.01U/mL (p<0.05), 0.03U/mL (p<0.01), and 0.05U/mL (HDL3 and
bin and thrombin+HDL3 or +liposomes were observed at 0.05U/mL (p<0.01) and
hrombin and thrombin+HDL3 or +liposomes were observed at 0.05U/mL (p<0.05)
lipoproteins nor liposomes reduced the enzymatic activity of
thrombin.
Finally, we sought to examinewhether the negative effect of SR-
B agonists on platelets could bemediated by their cholesterol efﬂux
capacity. However, neither native HDL3 nor PS- or PI-containing
liposomes decreased the platelet total cholesterol content dur-
ing the 5min incubation period, which was sufﬁcient to produce
inhibitory effects on platelet activation (not shown).3.3. The inhibitory effect of HDL3 on platelet activation is
enhanced by PS enrichment
As pointed above, anionic phospholipids serve as SR-B lig-
ands and determine the inhibitory effects of liposomes on
M.F. Brodde et al. / Atherosclerosis 215 (2011) 374–382 379
Fig. 3. Enrichment in phosphatidylserine (PS) potentiates inhibitory effect of HDL3 on the thrombin-induced activation of human platelets. (A–D) Human washed platelets
were stimulated with thrombin (0.02U/mL) in the presence or absence of native HDL3 (0.5 g/L) or HDL3 enriched with 0.5% (w/w) PS (HDL3-PS/0.5) or 1% (w/w) PS (HDL3-
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omparison. Maximal stimulation with thrombin was set as 100%. Data from panel
**p<0.001 thrombin vs. thrombin+HDL3 +HDL2 or +PS-enriched HDL3.
latelet activation. To speciﬁcally address the signiﬁcance of
nionic phospholipids for HDL3–platelet interactions, we enriched
DL3 with various amounts of PS. The anionic phospholipid
PS+PI) content in HDL3 particles increased from 23.3±2.7g/mg
rotein in native lipoproteins to 43.9±4.5g/mg protein and
2.8±5.1g/mg protein in HDL3 enriched with 0.5% (w/w) and
.0% (w/w) PS, respectively. By contrast, the content of phos-
hatidylcholine was not signiﬁcantly changed. When incubated
or 5min with the platelet suspension prior to stimulation with
hrombin (0.02U/mL), PS-enriched HDL3 (0.5 g/L) more potently
nhibited platelet aggregation and intracellular calcium mobiliza-
ion than native HDL3 (Fig. 3A and B). Moreover, the capacity of
S-enrichedHDL3 to attenuate thrombin-induced [Ca2+]i elevation
as related to the PS content in lipoprotein particles (Fig. 3C and
).
As HDL subfractions contain variable amounts of phospho-
ipids, we additionally determined the PS content in HDL2.
his HDL subfraction contains substantially less anionic phos-
holipids (PS +PI) than HDL3 (5.3±0.9g/mg protein), but
comparable amount of PC. Moreover, thrombin-induced
latelet aggregation and [Ca2+]i elevation were not signiﬁ-
antly changed in platelets exposed to HDL2 (Fig. 3E and
).thrombin stimulation. Panels A and C show original tracings superimposed for
d D–F represent means± SD from 3 independent experiments. *p<0.05; **p<0.01
3.4. SR-B ligands promote DAG release and activate PKC in
human platelets
We previously demonstrated that the phosphatidylcholine-
speciﬁc phospholipase C (PC-PLC)-dependent release of DAG and
the ensuing PKC activation are prerequisites for attenuated func-
tional responses of platelets exposed to HDL3 [11]. Therefore, we
next compared the effects of HDL3 and SR-B agonists on DAG
production and PKC activity. In agreement with previous obser-
vations, physiological concentrations of HDL3 (1.0 g/L) triggered
the formation of [14C]DAG in [14C]AA-labeled platelets (Fig. 4A).
Both PS- and PI-containing liposomes (0.5 g/L, PC:PS and PI:PC ratio
1:1, mol/mol) fully emulated the stimulating effect of HDL3 on
[14C]DAG production, while liposomes containing only PC were
without effect. Moreover, incubation of platelets for 1min with
HDL3, PS- or PI-containing liposomes resulted in phosphorylation
of the 40–47kD major protein substrate, which is considered to
be a marker of PKC activation in platelets (Fig. 4B). To assess the
relevance of the DAG-dependent PKC activation for the inhibitory
effects exerted by PS- or PI-containing liposomes on platelet
activation, platelet suspensions were pre-incubated with D609
(20.0mol/L), a PC-PLC inhibitor, orwith staurosporin (5.0mol/L)
or bis-indoylmaleylimide (5.0mol/L), two structurally distinct
380 M.F. Brodde et al. / Atherosclerosis 215 (2011) 374–382
Fig. 4. Scavenger receptor type B ligands induce intracellular signaling cascades in
human platelets. (A and B) Human washed platelets labeled with [14C]arachidonic
acid or [33P]orthophosphoric acid were incubated in the presence of HDL3 (1.0 g/L,
), PC-liposomes (0.5 g/L, ©), PS-liposomes (0.5 g/L,) or PI-liposomes (0.5 g/L, )
and analyzed for [14C]DAG (A) and protein phophorylation (1min incubation; B) as
described under Section 2. The arrow indicates p43 PKC phosphorylation substrate.
Data represent mean± SD or are representative for 3 independent experiments. (C)
Human platelets pre-incubated for 10min with D609 (20mol/L), staurosporine
(Str, 10mol/L), or bisindoylmaleimide (Bis, 1.0mol/L) were stimulated with
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Fig. 5. Inhibitory effect of PS-liposomes on the thrombin-induced activation of
murine platelets is abolished in SR-BI deﬁciency. Platelet-rich plasmas (PRP) from
wild type (A and B), SR-BI−/− (C andD) or CD36−/− (E and F)mice orwashed platelets
from wild type (G and H) or SR-BI−/− (I and J) mice were incubated with increasinghrombin (0.02U/mL) in the absence or presence of HDL3, PS-liposomes or PI-
iposomes and Ca2+ mobilization was determined. as described under Section 2.
ata represent mean± SD from 3–5 independent experiments. *p<0.05; **p<0.01
hrombin+HDL3 vs. thrombin+HDL3+ inhibitor.
KC inhibitors, prior to exposure to HDL3 or liposomes and stim-
lation with thrombin (0.02U/mL). As shown in Fig. 4C, the
nhibitory effects of both HDL3 and PS- or PI-containing liposomes
n thrombin-inducedCa2+ mobilizationwere abolished in platelets
re-treated with PC-PLC or PKC inhibitors.
.5. SR-BI mediates the inhibition of platelet activation by HDL3
nd SR-B agonists in mouse platelets
HDL3 and anionic liposomes serve as ligands for SR-BI and
D36, which are both expressed on the platelet surface. To speciﬁ-
ally address the identity of class B scavenger receptors mediating
he HDL3- or anionic liposomes-dependent inhibition of platelet
ctivation, we initially examined the effects of PS-containing lipo-
omes on FITC-conjugated ﬁbrinogen and anti-CD62 binding in
ouse platelet-rich plasma (PRP). As shown in Fig. 5A–F, addition
f thrombin to PRP promoted ﬁbrinogen binding and CD62 sur-
ace expression in a concentration-dependent fashion in platelets
rom wild type (WT), SR-BI−/− and CD36−/− mice. Pre-incubation
f PRP for 5min with PS-containing liposomes (0.5 g/L, PC:PS ratio
:1, mol/mol) signiﬁcantly attenuated platelet activation in PRP
rom WT and CD36−/− mice but not SR-BI−/− mice. Next, we exam-
ned the inﬂuence of native HDL3 and PS-containing liposomes on
he thrombin-inducedﬁbrinogen and anti-CD62binding inwashed
urine platelets. Fig. 5G–J demonstrates that both responses were
timulated by thrombin in a concentration-dependent manner andconcentrations of thrombin in the absence (©) or presence of HDL3 (1.0 g/L, ) or
PS-liposomes (0.5 g/L,). A, C, E, G, I ﬁbrinogen binding, B, D, F, H, J CD62 expression.
Data represent mean± SD from 4–6 independent experiments. #p<0.05 HDL3 vs.
control, *p<0.05 PS-liposomes vs. control.
attenuated in WT platelets pre-incubated for 5min with either
HDL3 (1.0 g/L) or PS-containing liposomes (0.5 g/L, PC:PS ratio 1:1,
mol/mol). By contrast, both HDL3 and PS-containing liposomes
failed to affect thrombin-inducedﬁbrinogenandanti-CD62binding
in washed platelets obtained from SR-BI−/− mice.
4. Discussion
Most work to date strongly supports a direct inhibitory effect
of HDL or their major fraction, HDL3, on platelet activation and
the subsequent formation of venous and arterial thrombi [7–10].
However, the mechanism underlying the anti-platelet effect of
HDL remains enigmatic. Our combined data provide several pieces
of evidence consistent with the direct involvement of scavenger
receptor type BI in the interaction betweenHDL and platelets. First,
structurally distinct synthetic SR-BI ligands interfered with HDL3
binding to platelets, while ligands of scavenger receptor type A
were ineffective in this respect. Second, SR-BI ligands fully mim-
icked the biological effects of HDL3 with regard to inhibition of
thrombin-induced washed platelet aggregation, mobilization of
intracellular calcium, granule secretion, and binding of ﬁbrinogen
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o the platelet surface. In addition, synthetic SR-BI ligands substi-
uted native HDL with respect to platelet activation in platelet-rich
lasma. Third, the intracellular signaling cascade comprising the
AG liberation from phosphatidylcholine and PKC activation was
riggered equally effectively in platelets exposed to HDL3 or SR-BI
igands. Fourth, the inhibitory effects of HDL3 and synthetic SR-BI
igandson thrombin-inducedﬁbrinogenbindingandgranule secre-
ionwere completely abolished in SR-BI-deﬁcientmurine platelets.
y contrast, these effects were preserved in platelets deﬁcient in
D36. Taken together, these ﬁndings corroborate the hypothesis
hat SR-BI is a functional HDL3 receptor on platelets mediating the
nhibitory effects of these lipoproteins on agonist-induced platelet
ctivation.
Previous studies regarding the identity of the HDL receptor on
he platelet surface led to conﬂicting results. Early ligand-blotting
xperiments suggested that the integrin IIb3 may serve as an
DL binding partner [25]. However, observations demonstrating
naltered binding of HDL particles to platelets in the presence of
nti-IIb3 antibodies orIIb3 ligands such as vitronectin and von
illebrand factor argued against a role of this integrin as a platelet
eceptor for HDL [26]. A splice variant of ApoER2/LRP8, a mem-
er of the LDL receptor family, has been proposed as a platelet
eceptor for the apolipoprotein E (apoE)-rich HDL subfraction
27,28]. However, HDL obtained from apoE-deﬁcient individuals
etained an inhibitory effect on platelet activation thereby exclud-
ng apoER2/LRP8 as the sole HDL receptor on platelets [29]. SR-BI
xpression on the platelet surface has been identiﬁed in two inde-
endent studies but no formal evidence documenting its role in
ediating HDL–platelet interactions has been presented to date
30,31]. TheHDL3 binding characteristics and the results of compe-
ition experiments shown here for the ﬁrst time point to scavenger
eceptor class B as a binding partner for native HDL3 on human
latelets. Moreover, the results of functional studies documenting
bolished inhibitory effects of HDL3 on agonist-stimulated ﬁbrino-
en binding and granule secretion inmurine platelets lacking SR-BI
rovideunequivocal evidence that this receptor is actually required
or native HDL3 to inhibit platelet activation. Our ﬁndings are in
oncordance with previous results of Imachi et al., who noted a
trong inverse relationship between the SR-BI abundance in human
latelets and the extent of ADP-induced platelet aggregation [30].
ogether with the results of the present study, these ﬁndings sug-
est that HDL3 exert a continuous suppressing effect on platelet
eactivity via SR-BI and may provide a mechanistic explanation
or the increased incidence of thrombosis in subjects with hypo-
-lipoproteinemia.
In addition to SR-BI, HDL has been demonstrated to serve
s a ligand for CD36 another member of the class B scavenger
eceptor superfamily present on the platelet surface. However,
he absence of CD36 in platelets failed to inﬂuence the inhibitory
ffect of HDL3 on thrombin-induced platelet ﬁbrinogen binding
nd granule secretion. CD36 on macrophages facilitates cellular
ptake of oxidized lipoproteins and therefore is believed to play
pro-atherogenic role, while SR-BI is atheroprotective by virtue of
articipating in the reverse cholesterol transport. CD36 onplatelets
as been previously reported to bind both oxidized LDL and/or
hospholipids thereby resulting in the enhanced platelet response
o agonists [32,33]. By demonstrating blunted platelet reactivity
s a consequence of SR-BI engagement, the present study suggests
hat both class B scavenger receptors may play an opposite role
ot only in context of atherosclerosis but also thrombosis: while
D36 promotes a prothrombotic phenotype, SR-BI might counter-
ct thrombus formation by suppressing platelet activation.
Recently, Valijaveettil et al. reported that oxidatively modiﬁed
DL (oxHDL) act as a potent inhibitor of platelet activation and
ggregation by physiologic agonists and, based on the results of
xperiments with SR-BI-deﬁcient platelets or anti-SR-BI blockingsis 215 (2011) 374–382 381
antibody, attributed these effects to SR-BI [31]. These ﬁndings are
inmajor contradiction to previously published data, which demon-
strated that Cu2+- or hypochlorite-oxidized HDL autonomously
induceplatelet aggregationor at least enhance aggregationbrought
about by other agonists [32,34,35]. In addition, increased gran-
ule secretion and elevated intracellular Ca2+ levels were observed
in platelets exposed to oxHDL. The results of the present study
demonstrating that the negative charge of the ligand, both native
(HDL3) and synthetic (liposomes), is critical to SR-BI-mediated
suppression of platelet reactivity may help to at least partially
resolve this discrepancy. Conceivably, exposure of HDL to more
mild oxidative conditions, such as short-term incubationwithCu2+,
preferentially leads to generation of oxidized phospholipids, which
would be expected to increase the negative charge of HDL par-
ticles and thereby their afﬁnity to SR-BI and the propensity to
suppress platelet reactivity. On the other hand, strong HDL oxi-
dation by hypochlorite might alter the apolipoprotein moiety of
HDL particles generating an effective ligand for the prothrombotic
CD36.
Recently, Calkin et al. found that reconstituted HDL parti-
cles (rHDL) containing apoA-I and phospholipids dramatically
reduced platelet free cholesterol content and inhibited the
ADP-induced platelet aggregation and granule secretion in a
receptor-independent fashion [36]. However, native HDL particles
were much less effective in removing cholesterol from platelets
and in much contrast to the present study failed to affect platelet
aggregation in response to ADP. While reasons for these discrep-
ancies are currently unclear, it has to be stressed that native HDL
in concentrations considerably below physiological levels were
used by Calkin et al. In addition, these authors used rHDL pre-
incubation times between 30min and 2h, which were apparently
necessary to effectively deplete platelet cholesterol. It cannot be
excluded, therefore, that anti-platelet effects ofnative and reconsti-
tuted HDL particles are mediated by entirely distinct mechanisms:
while native HDL inﬂuences platelet function via interaction with
speciﬁc receptors and induction of intracellular signaling cas-
cades, rHDL decreases platelet reactivity by promoting cholesterol
efﬂux and altering physicochemical properties of the plasma
membrane.
The recognition that the negative charge is a critical deter-
minant of the HDL-mediated suppression of platelet reactivity
may have far-reaching consequences for understanding the anti-
thrombotic effects attributed to these lipoproteins. The results
of the present study predict that HDL particles/subclasses abun-
dant in phosphatidylserine and/or phosphatidylinositol are more
efﬁcacious in preventing platelet activation and thereby might bet-
ter countervail the formation of intravascular thrombi. Actually,
only minor inhibitory effects on thrombin-induced platelet acti-
vation were seen in the presence of HDL2, which is a lipoprotein
subfraction characterized by a low amount of negatively charged
phospholipids. Differences in phosphatidylserine and/or phos-
phatidylinositol content in HDL particlesmight also account for the
individual susceptibility to thrombosis in subjects with low HDL
concentrations. Unfortunately, concentrations of anionic phospho-
lipids in patients with atherothrombotic vascular disease have not
been examined to date. Likewise, little is known about molecular
mechanisms controlling phosphatidylserine and/or phosphatidyli-
nositol transfer to and their exchange among HDL particles.
Delineation of these mechanisms might improve the assessment
of the risk of thrombosis and provide a platform for development
of new drugs for its treatment.In conclusion, the results of the present study suggest that SR-BI
is a functional receptor for native HDL3 on platelets that generates
inhibitory signals for platelet activation. The content of negatively
charged phospholipids in HDL may be an important determinant
of their anti-thrombotic potential.
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